Apremilast retention rate in clinical practice: observations from an Italian multi-center study
Objective There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence. Methods In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan–Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant. Results The 356 enrolled patients (median age 60 [interquartile range IQR 52–67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7–34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96–0.99; p = 0.048 and 0.54 IQR 0.31–0.95; p = 0.03). Conclusion Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points• Apremilast retention rates in this real-life cohort and trials are comparable.• The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years).• No different or more prevalent adverse events were observed..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 41(2022), 10 vom: 07. Juli, Seite 3219-3225 |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 |
|---|
| doi: |
10.1007/s10067-022-06255-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079564331 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079564331 | ||
| 003 | DE-627 | ||
| 005 | 20230512232114.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-022-06255-3 |2 doi | |
| 035 | |a (DE-627)OLC2079564331 | ||
| 035 | |a (DE-He213)s10067-022-06255-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Ariani, Alarico |e verfasserin |0 (orcid)0000-0003-1428-6102 |4 aut | |
| 245 | 1 | 0 | |a Apremilast retention rate in clinical practice: observations from an Italian multi-center study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022 | ||
| 520 | |a Objective There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of apremilast 3-year retention rate in real-world PsA patients. Moreover, the secondary objective is to report the reasons of apremilast discontinuation and the factors related to treatment persistence. Methods In fifteen Italian rheumatological referral centers, all PsA consecutive patients who received apremilast were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline were recorded. The Kaplan–Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant. Results The 356 enrolled patients (median age 60 [interquartile range IQR 52–67] yrs; male prevalence 42.7%) median observation period was 17 [IQR 7–34] months (7218 patients-months). The apremilast retention rate at 12, 24, and 36 months was, respectively, 85.6%, 73.6%, and 61.8%. The main discontinuation reasons were secondary inefficacy (34% of interruptions), gastro-intestinal intolerance (24%), and primary inefficacy (19%). Age and oligo-articular phenotype were related to treatment persistence (respectively hazard ratio 0.98 IQR 0.96–0.99; p = 0.048 and 0.54 IQR 0.31–0.95; p = 0.03). Conclusion Almost three-fifths of PsA patients receiving apremilast were still in treatment after 3 years. This study confirmed its effectiveness and safety profile. Apremilast appears as a good treatment choice in all oligo-articular PsA patients and in those ones burdened by relevant comorbidities. Key Points• Apremilast retention rates in this real-life cohort and trials are comparable.• The oligo-articular phenotype is associated with long-lasting treatment (i.e., 3 years).• No different or more prevalent adverse events were observed. | ||
| 650 | 4 | |a Apremilast | |
| 650 | 4 | |a Drug retention rate | |
| 650 | 4 | |a Psoriatic arthritis | |
| 700 | 1 | |a Parisi, Simone |0 (orcid)0000-0003-4496-8315 |4 aut | |
| 700 | 1 | |a Del Medico, Patrizia |4 aut | |
| 700 | 1 | |a Farina, Antonella |4 aut | |
| 700 | 1 | |a Visalli, Elisa |0 (orcid)0000-0002-8213-5528 |4 aut | |
| 700 | 1 | |a Molica Colella, Aldo Biagio |0 (orcid)0000-0002-7238-7879 |4 aut | |
| 700 | 1 | |a Lumetti, Federica |0 (orcid)0000-0003-4671-7982 |4 aut | |
| 700 | 1 | |a Caccavale, Rosalba |4 aut | |
| 700 | 1 | |a Scolieri, Palma |0 (orcid)0000-0002-2055-7282 |4 aut | |
| 700 | 1 | |a Andracco, Romina |0 (orcid)0000-0001-8933-2789 |4 aut | |
| 700 | 1 | |a Girelli, Francesco |0 (orcid)0000-0002-6075-9989 |4 aut | |
| 700 | 1 | |a Bravi, Elena |0 (orcid)0000-0002-4416-2568 |4 aut | |
| 700 | 1 | |a Colina, Matteo |0 (orcid)0000-0002-1174-2849 |4 aut | |
| 700 | 1 | |a Volpe, Alessandro |0 (orcid)0000-0002-4690-1205 |4 aut | |
| 700 | 1 | |a Ianniello, Aurora |4 aut | |
| 700 | 1 | |a Franchina, Veronica |4 aut | |
| 700 | 1 | |a Platè, Ilaria |4 aut | |
| 700 | 1 | |a Di Donato, Eleonora |0 (orcid)0000-0002-5466-3446 |4 aut | |
| 700 | 1 | |a Amato, Giorgio |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |0 (orcid)0000-0001-5426-5133 |4 aut | |
| 700 | 1 | |a Lucchini, Gianluca |0 (orcid)0000-0002-8685-1011 |4 aut | |
| 700 | 1 | |a De Lucia, Francesco |0 (orcid)0000-0002-2234-511X |4 aut | |
| 700 | 1 | |a Molica Colella, Francesco |4 aut | |
| 700 | 1 | |a Santilli, Daniele |0 (orcid)0000-0001-6640-7821 |4 aut | |
| 700 | 1 | |a Ferrero, Giulio |4 aut | |
| 700 | 1 | |a Marchetta, Antonio |0 (orcid)0000-0002-7916-8214 |4 aut | |
| 700 | 1 | |a Arrigoni, Eugenio |0 (orcid)0000-0003-2378-8243 |4 aut | |
| 700 | 1 | |a Mozzani, Flavio |0 (orcid)0000-0002-4738-9346 |4 aut | |
| 700 | 1 | |a Foti, Rosario |0 (orcid)0000-0002-7301-8362 |4 aut | |
| 700 | 1 | |a Sandri, Gilda |0 (orcid)0000-0003-0454-1093 |4 aut | |
| 700 | 1 | |a Bruzzese, Vincenzo |0 (orcid)0000-0001-7342-6350 |4 aut | |
| 700 | 1 | |a Paroli, Marino |0 (orcid)0000-0001-7919-9128 |4 aut | |
| 700 | 1 | |a Fusaro, Enrico |0 (orcid)0000-0001-9888-2563 |4 aut | |
| 700 | 1 | |a Becciolini, Andrea |0 (orcid)0000-0002-1051-8511 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d Springer International Publishing, 1982 |g 41(2022), 10 vom: 07. Juli, Seite 3219-3225 |w (DE-627)167914960 |w (DE-600)604755-5 |w (DE-576)024860131 |x 0770-3198 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:10 |g day:07 |g month:07 |g pages:3219-3225 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10067-022-06255-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 10 |b 07 |c 07 |h 3219-3225 | ||